(Q37473708)

20 August 2017

1 reference

title

Exploratory drug safety: a discovery strategy to reduce attrition in development (English)

1 reference

20 August 2017

Alan S Bass

1

1 reference

20 August 2017

Mark E Cartwright

2

1 reference

20 August 2017

Craig Mahon

3

1 reference

20 August 2017

Richard Morrison

4

1 reference

20 August 2017

Ronald Snyder

5

1 reference

20 August 2017

Paul McNamara

6

1 reference

20 August 2017

Prudence Bradley

7

1 reference

20 August 2017

Ying-Ying Zhou

8

1 reference

20 August 2017

John Hunter

9

1 reference

20 August 2017

publication date

5 May 2009

1 reference

Journal of Pharmacological and Toxicological Methods

20 August 2017

published in

1 reference

20 August 2017

volume

60

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

69-78

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

20 August 2017

1 reference

Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Moving towards better predictors of drug-induced torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Origins, practices and future of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Commentary: Discovery Toxicology--a nascent science.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

International Union of Pharmacology. XLIII. Compendium of voltage-gated ion channels: transient receptor potential channels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Comparison of the results of a modified miniscreen and the standard bacterial reverse mutation assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Assessment of renal injury in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

The role of early in vivo toxicity testing in drug discovery toxicology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Acquired QT interval prolongation and HERG: implications for drug discovery and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

International Union of Pharmacology. XLVI. G protein-coupled receptor list.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Animal models of ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Gastrointestinal-tract models and techniques for use in safety pharmacology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

International Union of Pharmacology. XLII. Compendium of voltage-gated ion channels: cyclic nucleotide-modulated channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

The state of innovation in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Innovation and greater probability of success in drug discovery and development -- from target to biomarkers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Can the pharmaceutical industry reduce attrition rates?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Benchmarking safety pharmacology regulatory packages and best practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Rapid in vivo oral screening in rats: reliability, acceptance criteria, and filtering efficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Impact of drug transporter studies on drug discovery and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Comparison of chlordimeform and carbaryl using a functional observational battery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Comprehensive non-clinical respiratory evaluation of promising new drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Principles of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Cellular basis of drug-induced torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Needed: system dynamics for the drug discovery process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Computational prediction of genotoxicity: room for improvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Evaluation of blood flow parameters in addition to blood pressure and electrocardiogram in the conscious telemetered beagle dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Role of the development scientist in compound lead selection and optimization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Translational medicine: can it really facilitate the transition of research "from bench to bedside"?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

Tissue and species distribution of mRNA for the IKr-like K+ channel, erg.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.194

10.1016/J.VASCN.2009.04.194

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference